Governance is Not Bureaucracy
In pharma, governance often becomes synonymous with bureaucracy — layers of approval committees that slow decisions without adding value. Effective program governance is the opposite: it clarifies decision rights, accelerates escalation, and ensures the right people make the right decisions at the right level.
Design Principles
- Tiered decision authority: workstream leads handle tactical decisions, program board handles cross-workstream trade-offs, steering committee handles strategic direction and investment
- Clear escalation triggers: quantified thresholds for scope, timeline, budget, and compliance deviations
- Decision velocity: maximum turnaround times at each governance tier
- Standing agenda discipline: every governance meeting has a structured decision agenda, not just status updates
- Quality and compliance integration: Quality/Regulatory representatives embedded in governance, not consulted ad hoc
Anti-Patterns to Avoid
Steering committees that review slide decks but defer all decisions. Program boards that re-discuss issues already resolved at workstream level. Governance structures designed for steady-state that don't adapt when programs enter crisis. Compliance reviews that occur at the end rather than being integrated throughout.